These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10199335)

  • 1. TNFA and TNFB polymorphisms in myasthenia gravis.
    Skeie GO; Pandey JP; Aarli JA; Gilhus NE
    Arch Neurol; 1999 Apr; 56(4):457-61. PubMed ID: 10199335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic disease associations in thymomatous myasthenia gravis.
    Amdahl C; Alseth EH; Gilhus NE; Nakkestad HL; Skeie GO
    Arch Neurol; 2007 Dec; 64(12):1729-33. PubMed ID: 18071035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour necrosis factor beta gene polymorphisms in myasthenia gravis.
    Zelano G; Lino MM; Evoli A; Settesoldi D; Batocchi AP; Torrente I; Tonali PA
    Eur J Immunogenet; 1998 Dec; 25(6):403-8. PubMed ID: 9949945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Titin and ryanodine receptor autoantibodies in dogs with thymoma and late-onset myasthenia gravis.
    Shelton GD; Skeie GO; Kass PH; Aarli JA
    Vet Immunol Immunopathol; 2001 Jan; 78(1):97-105. PubMed ID: 11182151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies.
    Romi F; Skeie GO; Aarli JA; Gilhus NE
    Arch Neurol; 2000 Nov; 57(11):1596-600. PubMed ID: 11074791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin.
    Gautel M; Lakey A; Barlow DP; Holmes Z; Scales S; Leonard K; Labeit S; Mygland A; Gilhus NE; Aarli JA
    Neurology; 1993 Aug; 43(8):1581-5. PubMed ID: 8351016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients.
    Yamamoto AM; Gajdos P; Eymard B; Tranchant C; Warter JM; Gomez L; Bourquin C; Bach JF; Garchon HJ
    Arch Neurol; 2001 Jun; 58(6):885-90. PubMed ID: 11405802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic contribution of the tumour necrosis factor (TNF) B + 252*2/2 genotype, but not the TNFa,b microsatellite alleles, to systemic lupus erythematosus in Japanese patients.
    Takeuchi F; Nakano K; Nabeta H; Hong GH; Kawasugi K; Mori M; Okudaira H; Kuwata S; Tanimoto K
    Int J Immunogenet; 2005 Jun; 32(3):173-8. PubMed ID: 15932622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?
    Buckley C; Newsom-Davis J; Willcox N; Vincent A
    Neurology; 2001 Nov; 57(9):1579-82. PubMed ID: 11706095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis.
    Chen XJ; Qiao J; Xiao BG; Lu CZ
    J Neurol; 2004 Aug; 251(8):1006-11. PubMed ID: 15316806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma.
    Baggi F; Andreetta F; Antozzi C; Simoncini O; Confalonieri P; Labeit S; Cornelio F; Mantegazza R
    Ann N Y Acad Sci; 1998 May; 841():538-41. PubMed ID: 9668290
    [No Abstract]   [Full Text] [Related]  

  • 12. Major histocompatibility complex class I chain related (MIC) A gene, TNFa microsatellite alleles and TNFB alleles in juvenile idiopathic arthritis patients from Latvia.
    Nikitina Zake L; Cimdina I; Rumba I; Dabadghao P; Sanjeevi CB
    Hum Immunol; 2002 May; 63(5):418-23. PubMed ID: 11975986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Titin, thymoma, and myasthenia gravis.
    Aarli JA
    Arch Neurol; 2001 Jun; 58(6):869-70. PubMed ID: 11405799
    [No Abstract]   [Full Text] [Related]  

  • 14. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with costimulatory molecules.
    Romi F; Bø L; Skeie GO; Myking A; Aarli JA; Gilhus NE
    J Neuroimmunol; 2002 Jul; 128(1-2):82-9. PubMed ID: 12098514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes.
    Skeie GO; Pandey JP; Aarli JA; Gilhus NE
    Autoimmunity; 1997; 26(2):111-6. PubMed ID: 9546812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
    Mygland A; Vincent A; Newsom-Davis J; Kaminski H; Zorzato F; Agius M; Gilhus NE; Aarli JA
    Arch Neurol; 2000 Apr; 57(4):527-31. PubMed ID: 10768628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis.
    Hjelmström P; Peacock CS; Giscombe R; Pirskanen R; Lefvert AK; Blackwell JM; Sanjeevi CB
    J Neuroimmunol; 1998 Aug; 88(1-2):137-43. PubMed ID: 9688335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum anti-titin antibody in patients with myasthenia gravis].
    Li YF; Zhang JB; Cui LY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Dec; 25(6):725-7. PubMed ID: 14714322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased TNFA*2, but not TNFB*1, allele frequency in Spanish atopic patients.
    Castro J; Tellería JJ; Linares P; Blanco-Quirós A
    J Investig Allergol Clin Immunol; 2000; 10(3):149-54. PubMed ID: 10923589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myasthenia gravis in individuals over 40.
    Aarli JA; Romi F; Skeie GO; Gilhus NE
    Ann N Y Acad Sci; 2003 Sep; 998():424-31. PubMed ID: 14592910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.